Friess Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Friess Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-59,800	Closed	-$14.2M	–	134
2020 Q1	$14.2M	Buy	59,800 +13,747	+30%	+$3.15M	1.42%	30
2019 Q4	$10.1M	Sell	46,053 -55,045	-54%	-$11.1M	0.7%	56
2019 Q3	$17.1M	Buy	101,098 +5,148	+5%	+$911K	1.32%	42
2019 Q2	$17.6M	Buy	+95,950	New	+$16.8M	1.28%	33
2018 Q1	–	Sell	-81,500	Closed	-$12.2M	–	120
2017 Q4	$12.2M	Buy	+81,500	New	+$12.1M	1.01%	51
2017 Q2	–	Sell	-145,000	Closed	-$15.9M	–	133
2017 Q1	$15.9M	Buy	+145,000	New	+$12.8M	1.49%	22

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Friess Associates's VRTX Position: Q2 2020 in Review

Friess Associates sold out of Vertex Pharmaceuticals (VRTX) in Q2 2020, closing a stake of 59,800 shares — an estimated $14.2M sold.

Friess Associates first reported a position in VRTX in Q1 2017 and held it in 6 quarters. The position peaked at $17.6M in Q2 2019. 963 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

Friess Associates reported no remaining Vertex Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Friess Associates sold 59,800 Vertex Pharmaceuticals shares in Q2 2020, an estimated $14.2M.
Friess Associates first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Friess Associates's Vertex Pharmaceuticals position peaked at $17.6M in Q2 2019.
963 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on Friess Associates's 13F filing for Q2 2020, filed 14 Aug 2020.